STUDIES & RESULTS
Clinical Validation of the Wellness Technologies.ai Platform
The Science and Data Behind Our Evidence-Based Technology.
In an industry filled with guesswork and empty promises, Wellness Technologies.ai was founded on a commitment to measurable, repeatable results. Our platform is not just a concept; it is a system with a long history of success, validated by independent, third-party clinical research.
We believe that true innovation requires proof. Here, we present the foundational studies that demonstrate the effectiveness of the core technology and protocols that power the Wellness Technologies.ai platform and are used by our network of licensed providers.
Foundational Research: Randomized Controlled Trial
This IRB-approved, double-blind, randomized, placebo-controlled trial was conducted to establish a scientific baseline for the core program protocol, even without the technology, personalization, or professional supervision our platform provides.
Top 25% of Participants
[lptw_table id=”1459″ style=”material-nm-gray”]
Key Findings:
Even in this unsupervised, non-personalized format, the group using the core protocol experienced a statistically significant average weight loss of 8.8 lbs in 45 days, compared to the placebo group. The top 10% of participants on the protocol lost an average of 24.25 pounds. This validates the foundational efficacy of the program’s core components.
Real-World Evidence: Prospective Longitudinal Case Study
This study was designed to measure the results when the full power of the technology is applied—including the technology driven personalization and provider monitoring. The data comes from first-time clients using the complete program.
50-75% of Participants
[lptw_table id=”1936″ style=”material-nm-gray”]
25-50% of Participants
[lptw_table id=”1943″ style=”material-nm-gray”]
Key Findings:
When the complete, personalized program is utilized, the results are dramatically amplified. The prospective study showed an average weight loss of 26.2 lbs on the 40-day program, with an incredible 14.3 lbs lost within the first 20 days.
A System Designed for Sustainability
One of the most critical measures of success is long-term sustainability. The research followed participants after the initial weight loss phase to measure their ability to maintain results.
Bottom 25% of Participants
[lptw_table id=”1944″ style=”material-nm-gray”]
Key Findings:
After completing the weight loss phase, participants continued to see success, losing an additional average of 1.4 lbs (RCT Trial) and 3.0 lbs (Prospective Study) respectively. This demonstrates that the technology is designed not for a temporary fix, but to support metabolic pathways that promote lasting results and health.
Prospective Longitudinal Cohort Case Study Data comes from first-time client submitted data to a third party for tracking of daily weight loss and progress through the Wellness Technologies weight loss programs. All results are accurately and transparently presented.
IRB Approved Randomized Controlled Trial was sponsored by Wellness Technologies and conducted by an independent contract research organization (Global Clinicals, Inc., Los Angeles, CA).
STUDY COMPARISON
PROSPECTIVE LONGITUDINAL COHORT ANALYSIS
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
GOALS
To assess the efficacy of the personalized & supervised 40-Day weight loss program
To determine short-term weight loss sustainability of the personalized 40-day weight loss program
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
GOALS
To assess the efficacy of the nonpersonalized and unsupervised 40-Day weight Loss Program
To determine the safety of the 40-Day weight loss program by utilizing blood work, vitals & assessment questionnaires.
To assess medium-term weight loss sustainability (2.25 months after the weight loss phase)
PROSPECTIVE LONGITUDINAL COHORT ANALYSIS
PERSONALIZED
The weight loss program was personalized and optimized for each individual user regarding both foods and supplementation
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
NONPERSONALIZED
The protocols were the same for each user. Each user was given the same list of foods and were all placed on the same 4 nutritional products.
PROSPECTIVE LONGITUDINAL COHORT ANALYSIS
SUPERVIZED
Each user was assigned a personal coach who had access to user’s daily weights. User could contact coach daily and would meet each week to review results and make adjustments to help coach and guide the user to success.
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
UNSUPERVISED
The user had four set meetings (including the 1st visit) with a researcher, whose job was merely to gather information and could not intervene or provide guidance or coaching.
PROSPECTIVE LONGITUDINAL COHORT ANALYSIS
RESOURCES AND TOOLS
The user was given a number of resources and tools including member only user portal, which provided an abundance of resources, as well as, advanced email and text support.
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
MANUAL
No resources or tools were given to the user except a “generic” manual / guide.
PROSPECTIVE LONGITUDINAL COHORT ANALYSIS
SAMPLE SIZE
The sample size of the study was large at 4,505 users
IRB APPROVED RANDOMIZED PLACEBO-CONTROLLED TRIAL
SAMPLE SIZE
The sample size of the study started at 120 participants. 60 Active and 60 control. The trial ended with 36 active participants and 33 control participants.
STUDY COMPARISON
Maximum Weight Loss Attained over 40 days, by Quartile
Cumulative Weight Loss Over Time
IRB APPROVED DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL:
Lipid Panel-Change from Baseline Day 45[lptw_table id=”1509″ style=”material-nm-gray”]
Lipid Panel-Change from Baseline Day 21[lptw_table id=”1476″ style=”material-nm-gray”]
Conclusion: Technology Built on Proof
The evidence is clear. The foundational protocols of the Wellness Technologies.ai platform are scientifically sound, and when the full power of our A.I. personalization and remote monitoring is unlocked, the results are fast, significant, and sustainable.
We provide this technology to empower wellness providers to deliver the highest level of evidence-based care to their clients.